208 related articles for article (PubMed ID: 19399518)
1. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy.
Wilop S; von Hobe S; Crysandt M; Esser A; Osieka R; Jost E
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1429-35. PubMed ID: 19399518
[TBL] [Abstract][Full Text] [Related]
2. Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC.
Miao L; Chen W; Zhou L; Wan H; Gao B; Feng Y
Sci Rep; 2016 Feb; 6():21359. PubMed ID: 26883083
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma.
Chen YH; Huang CH; Lu HI; Chen CH; Huang WT; Hsieh MJ; Rau KM; Chang AY; Lin WC; Li SH
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1185-92. PubMed ID: 24961505
[TBL] [Abstract][Full Text] [Related]
4. How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy?
Kim ST; Park KH; Oh SC; Seo JH; Kim JS; Shin SW; Kim YH
Oncology; 2012; 83(6):354-60. PubMed ID: 23052034
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
Heinze G; Mitterbauer C; Regele H; Kramar R; Winkelmayer WC; Curhan GC; Oberbauer R
J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment Serum Albumin Level is an Independent Prognostic Factor in Patients with Stage IIIB Non-Small Cell Lung Cancer: A Study of the Turkish Descriptive Oncological Researches Group.
Tanriverdi O; Avci N; Oktay E; Kalemci S; Pilanci KN; Cokmert S; Menekse S; Kocar M; Sen CA; Akman T; Ordu C; Goksel G; Meydan N; Barutca S
Asian Pac J Cancer Prev; 2015; 16(14):5971-6. PubMed ID: 26320482
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine plus paclitaxel as second-line chemotherapy in patients with advanced non-small cell lung cancer.
Baykara M; Coskun U; Berk V; Ozkan M; Kaplan MA; Benekli M; Karaca H; Inanc M; Isikdogan A; Sevinc A; Elkiran ET; Demirci U; Buyukberber S
Asian Pac J Cancer Prev; 2012; 13(10):5119-24. PubMed ID: 23244121
[TBL] [Abstract][Full Text] [Related]
8. Predictive and prognostic factors in second- and third-line erlotinib treatment in NSCLC patients with known status of the EGFR gene.
Krawczyk P; Kowalski DM; Krawczyk KW; Szczyrek M; Mlak R; Rolski A; Szudy A; Kieszko R; Winiarczyk K; Milanowski J; Krzakowski M
Oncol Rep; 2013 Sep; 30(3):1463-72. PubMed ID: 23783797
[TBL] [Abstract][Full Text] [Related]
9. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Kim HT; Lee JE; Shin ES; Yoo YK; Cho JH; Yun MH; Kim YH; Kim SK; Kim HJ; Jang TW; Kwak SM; Kim CS; Ryu JS
J Clin Oncol; 2008 Dec; 26(36):5972-9. PubMed ID: 19018088
[TBL] [Abstract][Full Text] [Related]
10. Distinct survival benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers in revascularized coronary artery disease patients according to history of myocardial infarction.
Nishino T; Furukawa Y; Kaji S; Ehara N; Shiomi H; Kim K; Kitai T; Kinoshita M; Morimoto T; Sakata R; Kimura T;
Circ J; 2013; 77(5):1242-52. PubMed ID: 23291989
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy in non small cell lung cancer stage IIIa-b and IV and second-line treatment.
Stathopoulos GP; Dafni UG; Malamos NA; Rigatos S; Kouvatseas G; Moschopoulos N
Anticancer Res; 1999; 19(4C):3543-8. PubMed ID: 10629650
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system blockade and kidney transplantation: a longitudinal cohort study.
Hernández D; Muriel A; Abraira V; Pérez G; Porrini E; Marrero D; Zamora J; González-Posada JM; Delgado P; Rufino M; Torres A
Nephrol Dial Transplant; 2012 Jan; 27(1):417-22. PubMed ID: 21622985
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers (ACEI/ARB) are Associated with Improved Limb Salvage after Infrapopliteal Interventions for Critical Limb Ischemia.
Khan SZ; Montross B; Rivero M; Cherr GS; Harris LM; Dryjski ML; Dosluoglu HH
Ann Vasc Surg; 2020 Feb; 63():275-286. PubMed ID: 31626938
[TBL] [Abstract][Full Text] [Related]
14. Screening for patients with non-small cell lung cancer who could survive long term chemotherapy.
Wu XY; Huang XE
Asian Pac J Cancer Prev; 2015; 16(2):647-52. PubMed ID: 25684501
[TBL] [Abstract][Full Text] [Related]
15. First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Maemondo M; Minegishi Y; Inoue A; Kobayashi K; Harada M; Okinaga S; Morikawa N; Oizumi S; Tanaka T; Isobe H; Kudoh S; Hagiwara K; Nukiwa T; Gemma A
J Thorac Oncol; 2012 Sep; 7(9):1417-22. PubMed ID: 22895139
[TBL] [Abstract][Full Text] [Related]
16. Comparison Between Beta-Blockers with Angiotensin-Converting Enzyme Inhibitors and Beta-Blockers with Angiotensin II Type I Receptor Blockers in ST-Segment Elevation Myocardial Infarction After Successful Percutaneous Coronary Intervention with Drug-Eluting Stents.
Kim YH; Her AY; Jeong MH; Kim BK; Lee SY; Hong SJ; Shin DH; Kim JS; Ko YG; Choi D; Hong MK; Jang Y
Cardiovasc Drugs Ther; 2019 Feb; 33(1):55-67. PubMed ID: 30632033
[TBL] [Abstract][Full Text] [Related]
17. A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
Levitan N; Dowlati A; Craffey M; Tahsildar H; MacKay W; McKenney J; Remick SC
Lung Cancer; 1998 Dec; 22(3):227-34. PubMed ID: 10048475
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine.
Nakai Y; Isayama H; Ijichi H; Sasaki T; Sasahira N; Hirano K; Kogure H; Kawakubo K; Yagioka H; Yashima Y; Mizuno S; Yamamoto K; Arizumi T; Togawa O; Matsubara S; Tsujino T; Tateishi K; Tada M; Omata M; Koike K
Br J Cancer; 2010 Nov; 103(11):1644-8. PubMed ID: 20978506
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
Akerley W; Boucher KM; Bentz JS; Arbogast K; Walters T
J Thorac Oncol; 2009 Feb; 4(2):214-9. PubMed ID: 19179899
[TBL] [Abstract][Full Text] [Related]
20. ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Ozdemir O; Ozdemir P; Veral A; Uluer H; Ozhan MH
Asian Pac J Cancer Prev; 2013; 14(8):4679-83. PubMed ID: 24083725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
